[go: up one dir, main page]

AR035011A1 - VLA-4 INHIBITING COMPOUNDS - Google Patents

VLA-4 INHIBITING COMPOUNDS

Info

Publication number
AR035011A1
AR035011A1 ARP000103363A ARP000103363A AR035011A1 AR 035011 A1 AR035011 A1 AR 035011A1 AR P000103363 A ARP000103363 A AR P000103363A AR P000103363 A ARP000103363 A AR P000103363A AR 035011 A1 AR035011 A1 AR 035011A1
Authority
AR
Argentina
Prior art keywords
substituted
formula
alkyl
aryl
lower alkyl
Prior art date
Application number
ARP000103363A
Other languages
Spanish (es)
Inventor
John Baldwin
Edward Mcdonald
Kevin Joseph Moriarty
Christopher Ronald Sarko
Nobuo Machinaga
Atsushi Nakayama
Jun Chiba
Shin Iimura
Yoshiyuki Yoneda
Original Assignee
Daiichi Seiyaku Co
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co, Pharmacopeia Inc filed Critical Daiichi Seiyaku Co
Publication of AR035011A1 publication Critical patent/AR035011A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal del mismo donde: W es seleccionado entre arilo, arilo sustituido, heteroarilo y heteroarilo sustituido; W1 es seleccionado entre arileno, arileno sustituido, heteroarileno y heteroarileno sustituido; A es seleccionado entre =O, =S y =NH; R es seleccionado entre un enlace directo, un grupo alquenileno y -(CH2)n, donde n es seleccionado entre 1 y 2; X es seleccionado entre -C(O)-, -CH2- y -S(O)2-; M es seleccionado entre radicales del grupo de fórmulas (2a), (2b), (2c) ó (2d) donde: el resto de fórmula (3) es un resto heterocíclico divalente de 4, 5, 6 o 7 miembros, donde el átomo de nitrógeno es el punto de unión a X; R1, R2 y R3 son seleccionados independientemente entre -H, -OH, -NH2, átomo de halógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, alcoxi, alcoxi sustituido, monoalquilamino, monoalquilamino sustituido, dialquilamino, dialquilamino sustituido, cicloalquilamino, cicloalquilamino sustituido, alquilsulfonilamino, alquilsulfonilamino sustituido, arilsulfonilamino, arilsulfonilamino sustituido, ariloxi, ariloxi sustituido, heteroariloxi, heteroariloxi sustituido, benciloxi y benciloxi sustituido, o aquellos dos radicales entre ellos forman juntos un residuo carbocíclico o heterocíclico de 3, 4, 5, 6 o 7 miembros eventualmente sustituido con 1 a 3 sustituyentes seleccionados independientemente entre -OH, átomo de halógeno, -NH2, alquilo, alcoxi, arilo, ariloxi, alquilamino, benciloxi y heteroarilo; R4 es seleccionado entre -H y alquilo inferior; Y es un enlace directo o un radical divalente seleccionado entre -C(O)-, -C(O)NH-, alquenileno, alquinileno y -(CH2)kY2-, donde k es seleccionado entre 1, 2 y 3 e Y2 es un enlace directo un radical divalente seleccionado entre -O-, -S-, -S(O)-, -S(O)2- y -NY3-, donde Y3 es seleccionado entre -H y alquilo inferior; Z es seleccionado entre arileno, arileno sustituido, heterociclileno, heterociclileno sustituido, cicloalquileno y cicloalquileno sustituido; A1 es un enlace directo o un radical divalente seleccionado entre alquenileno, alquinileno, -(CH2)t-, donde t es seleccionado entre 1, 2 y 3, y -O(CH2)v, donde v es seleccionado entre 0, 1, 2 y 3; y R5 es seleccionado entre -OH, alcoxi inferior, -NHOH, un resto de fórmula (4a) ó fórmula (4b); donde el resto fórmula (5) es un resto heterocíclico divalente de 4, 5 6 o 7 miembros, donde el átomo de nitrógeno es el punto de unión a X; R6 y R7 son independientemente seleccionados entre -H, -OH, átomo de halógeno, alquilo y alcoxi; Y1 es un radical divalente seleccionado entre -O-, -S-, -S(O)-, -S(O)2- y -NY4-, donde Y4 es seleccionado entre -H y alquilo inferior; Z1 es un radical divalente seleccionado entre arileno, arileno sustituido, heterociclileno, heterociclileno sustituido, cicloalquileno y cicloalquileno sustituido; A2 es un enlace directo o un radical divalente seleccionado entre alquenileno, alquinileno y -(CH2)e, donde e es seleccionado entre 1, 2 y 3, y R8 es seleccionado entre -OH, alcoxi inferior, -NHOH, un resto de fórmula (4a) ó (4b); donde L es de fórmula (6), donde su parte cíclica es un resto heterocíclico divalente de 4, 5, 6 o 7 miembros, eventualmente sustituido con 1 a 3 sustituyentes seleccionados independientemente entre alquilo, alcoxi, hidroxialquilo, -OH, benciloxi, -NH2, átomo de halógeno, arilo y heteroarilo, y dicho resto heterocíclico puede estar fusionado a 1 o 2 residuos carbocíclicos o heterocíclicos adicionales eventualmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados entre alquilo, ariloxi, alcoxi, hidroxialquilo, -OH, benciloxi, -NH2, átomo de halógeno, arilo y heteroarilo; m y g son independientemente seleccionados entre 0, 1, 2 y 3; X1 es seleccionado entre -CH= y -N=; R9 es seleccionado entre -H y alquilo inferior; R10 es seleccionado entre -CO2H, alcoxi-carbonilo inferior, un resto de fórmula (4a), (7) ó (8) y Z2 es seleccionado entre -H, -CO2H y grupo alcoxicarbonilo inferior; donde R11 es seleccionado entre -O-, o el grupo de fórmulas (9) y -NR12-, donde R12 es seleccionado entre -H, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, bencilo, bencilo sustituido, alquenilo inferior, alquenilo inferior sustituido y alquinilo inferior, donde el enlace de la izquierda es el punto de unión a X y el enlace de la derecha es el punto de unión a Z3; Z3 es seleccionado entre un enlace directo y un resto hidrocarbonado alifático divalente C1-12 y su uno o mas átomos de carbono pueden estar sustituidos con -O- o -NR13-, donde R13 es seleccionado entre -H y alquilo inferior; uno o más átomos de hidrógeno unidos a un átomo de carbono alifático pueden estar sustituidos con alquilo inferior, y fórmula (10), donde x es seleccionado entre 0 y 1; y es seleccionado entre 1, 2 y 3 y R14 es seleccionado entre -H, -OH y átomo de halógeno, o un resto del grupo (11), siempre que Z4 sea seleccionado entre los tres grupos divalentes formulados siguientes en el caso limitado de que R11 sea -NR12, fórmula (12) donde R14a es seleccionado entre -H, -OH, alquilo inferior y átomo de halógeno; un grupo de fórmulas (13), donde el enlace de la izquierda es el punto de unión a R11 y el enlace de la derecha es el punto de unión a Q2; Q2 es un radical divalente seleccionado entre arileno, arileno sustituido, heterociclileno, heterociclileno sustituido, cicloalquileno, cicloalquileno sustituido, formula (14), donde R15 y R16 son independientemente seleccionados entre -H, átomo de halógeno y alquilo inferior, y fórmula (15), donde R17 y R18 son independientemente seleccionados entre -H, alquilo inferior, alquilo inferior sustituido y alquenilo inferior, y L1 es seleccionado entre -CO2H y -CO2R19, donde R19 es un alquilo inferior.Claim 1: A compound represented by the formula (1), or a salt thereof wherein: W is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; W1 is selected from arylene, substituted arylene, heteroarylene and substituted heteroarylene; A is selected from = O, = S and = NH; R is selected from a direct link, an alkenylene group and - (CH2) n, where n is selected between 1 and 2; X is selected from -C (O) -, -CH2- and -S (O) 2-; M is selected from radicals of the group of formulas (2a), (2b), (2c) or (2d) where: the rest of formula (3) is a divalent heterocyclic moiety of 4, 5, 6 or 7 members, where the nitrogen atom is the point of attachment to X; R1, R2 and R3 are independently selected from -H, -OH, -NH2, halogen atom, alkyl, substituted alkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, monoalkylamino, substituted monoalkylamino, dialkylamino, substituted dialkylamino, cycloalkylamino, cycloalkylamino substituted, alkylsulfonylamino, substituted alkylsulfonylamino, arylsulfonylamino, substituted arylsulfonylamino, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, benzyloxy and substituted benzyloxy, or those two radicals together form a carbocyclic or heterocyclic residue of 3, 4, 5, 6, members optionally substituted with 1 to 3 substituents independently selected from -OH, halogen atom, -NH2, alkyl, alkoxy, aryl, aryloxy, alkylamino, benzyloxy and heteroaryl; R4 is selected from -H and lower alkyl; Y is a direct bond or a divalent radical selected from -C (O) -, -C (O) NH-, alkenylene, alkynylene and - (CH2) kY2-, where k is selected between 1, 2 and 3 and Y2 is a direct bond a divalent radical selected from -O-, -S-, -S (O) -, -S (O) 2- and -NY3-, where Y3 is selected from -H and lower alkyl; Z is selected from arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, cycloalkylene and substituted cycloalkylene; A1 is a direct bond or a divalent radical selected from alkenylene, alkynylene, - (CH2) t-, where t is selected from 1, 2 and 3, and -O (CH2) v, where v is selected from 0, 1, 2 and 3; and R5 is selected from -OH, lower alkoxy, -NHOH, a residue of formula (4a) or formula (4b); where the formula moiety (5) is a divalent heterocyclic moiety of 4, 5, 6 or 7 members, where the nitrogen atom is the point of attachment to X; R6 and R7 are independently selected from -H, -OH, halogen atom, alkyl and alkoxy; Y1 is a divalent radical selected from -O-, -S-, -S (O) -, -S (O) 2- and -NY4-, where Y4 is selected from -H and lower alkyl; Z1 is a divalent radical selected from arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, cycloalkylene and substituted cycloalkylene; A2 is a direct bond or a divalent radical selected from alkenylene, alkynylene and - (CH2) e, where e is selected from 1, 2 and 3, and R8 is selected from -OH, lower alkoxy, -NHOH, a remainder of formula (4a) or (4b); where L is of formula (6), where its cyclic part is a divalent heterocyclic moiety of 4, 5, 6 or 7 members, optionally substituted with 1 to 3 substituents independently selected from alkyl, alkoxy, hydroxyalkyl, -OH, benzyloxy, - NH2, halogen, aryl and heteroaryl atom, and said heterocyclic moiety may be fused to 1 or 2 additional carbocyclic or heterocyclic residues optionally substituted with 1 to 3 substituents independently selected from alkyl, aryloxy, alkoxy, hydroxyalkyl, -OH, benzyloxy, - NH2, halogen, aryl and heteroaryl atom; m and g are independently selected from 0, 1, 2 and 3; X1 is selected from -CH = and -N =; R9 is selected from -H and lower alkyl; R10 is selected from -CO2H, lower alkoxycarbonyl, a moiety of formula (4a), (7) or (8) and Z2 is selected from -H, -CO2H and lower alkoxycarbonyl group; where R11 is selected from -O-, or the group of formulas (9) and -NR12-, where R12 is selected from -H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, benzyl, substituted benzyl, lower alkenyl, substituted lower alkenyl and lower alkynyl, where the link on the left is the point of attachment to X and the link on the right is the point of attachment to Z3; Z3 is selected from a direct bond and a C1-12 divalent aliphatic hydrocarbon moiety and its one or more carbon atoms may be substituted with -O- or -NR13-, where R13 is selected from -H and lower alkyl; one or more hydrogen atoms attached to an aliphatic carbon atom may be substituted with lower alkyl, and formula (10), where x is selected from 0 to 1; and is selected between 1, 2 and 3 and R14 is selected from -H, -OH and halogen atom, or a remainder of the group (11), provided that Z4 is selected from the following three formulated divalent groups in the limited case of R11 is -NR12, formula (12) where R14a is selected from -H, -OH, lower alkyl and halogen atom; a group of formulas (13), where the link on the left is the point of attachment to R11 and the link on the right is the point of attachment to Q2; Q2 is a divalent radical selected from arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, cycloalkylene, substituted cycloalkylene, formula (14), where R15 and R16 are independently selected from -H, halogen atom and lower alkyl, and formula (15) , where R17 and R18 are independently selected from -H, lower alkyl, substituted lower alkyl and lower alkenyl, and L1 is selected from -CO2H and -CO2R19, where R19 is a lower alkyl.

ARP000103363A 1999-06-30 2000-06-30 VLA-4 INHIBITING COMPOUNDS AR035011A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14169299P 1999-06-30 1999-06-30
US14160199P 1999-06-30 1999-06-30
US14160299P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
AR035011A1 true AR035011A1 (en) 2004-04-14

Family

ID=27385682

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103363A AR035011A1 (en) 1999-06-30 2000-06-30 VLA-4 INHIBITING COMPOUNDS

Country Status (13)

Country Link
EP (1) EP1189612A4 (en)
JP (1) JP2003503350A (en)
CN (1) CN1391473A (en)
AR (1) AR035011A1 (en)
AU (1) AU781438B2 (en)
BR (1) BR0012068A (en)
CA (1) CA2369308A1 (en)
HK (1) HK1043318A1 (en)
IL (1) IL146288A0 (en)
MX (1) MXPA01013406A (en)
NO (1) NO324892B1 (en)
TW (1) TWI283240B (en)
WO (1) WO2001000206A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1324996A2 (en) 2000-01-17 2003-07-09 Bayer CropScience AG Substituted aryl ketones
DE10006453A1 (en) * 2000-02-14 2001-08-16 Bayer Ag New piperidylcarboxylic acid derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological diseases, e.g. atherosclerosis, asthma, diabetes, rheumatoid arthritis or transplant rejection
EP1296949A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
DE60222667T2 (en) 2001-06-27 2008-07-17 Smithkline Beecham Corp. FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
GB0123765D0 (en) * 2001-10-03 2001-11-21 Bayer Ag Para-amino benzoic acids
WO2003095421A1 (en) * 2002-05-09 2003-11-20 Mimotopes Pty Ltd Amino acid analogues
CN1678311A (en) 2002-06-27 2005-10-05 诺沃挪第克公司 Arylcarbonyl derivatives useful as therapeutic agents
CA2488642C (en) 2002-06-27 2011-09-06 Dharma Rao Polisetti Aryl carbonyl derivatives as glucokinase activators
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
GB0225944D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
EP1623975A4 (en) 2003-05-09 2008-07-02 Daiichi Seiyaku Co Process for producing pyrrolidine derivative
MXPA06000850A (en) 2003-07-24 2006-03-30 Daiichi Seiyaku Co Cyclohexanecarboxylic acid compound.
JP4667384B2 (en) * 2003-10-07 2011-04-13 レノビス， インコーポレイテッド Amide derivatives and pharmaceutical compositions as ion channel ligands and methods of using them
PL1723128T3 (en) 2004-01-06 2013-04-30 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
JP2005350417A (en) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd Method for producing pyrrolidine derivative using reductive etherification method
CN101006097B (en) * 2004-08-16 2012-07-11 默沙东公司 Vla-4 antagonists
WO2007069635A1 (en) 2005-12-13 2007-06-21 Daiichi Sankyo Company, Limited Vla-4 inhibitory drug
CN101827826A (en) 2007-10-16 2010-09-08 诺瓦提斯公司 4-phenyl-5-oxo-imidazole derivatives, pharmaceutical compositions and uses therof
EP2260020B1 (en) * 2008-03-26 2014-07-23 Novartis AG Hydroxamate-based inhibitors of deacetylases b
HRP20161461T1 (en) 2009-11-18 2017-01-27 Suven Life Sciences Limited Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands
JP5976011B2 (en) * 2011-04-05 2016-08-23 武田薬品工業株式会社 Sulfonamide derivatives and uses thereof
JP2021526130A (en) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー Therapeutic use of glucokinase activators in combination with insulin or insulin analogs
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
PL3873605T3 (en) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
DK3873884T3 (en) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
WO2020173861A1 (en) 2019-02-26 2020-09-03 Bayer Aktiengesellschaft Condensed bicyclic heterocyclic derivatives as pest control agents
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
AU1361499A (en) * 1997-10-21 1999-05-10 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
CA2303848C (en) * 1997-10-31 2008-09-30 Rhone-Poulenc Rorer Limited Substituted anilides
AU3716499A (en) * 1998-04-21 1999-11-08 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
HUP0102477A3 (en) * 1998-06-30 2002-08-28 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds

Also Published As

Publication number Publication date
EP1189612A4 (en) 2005-02-16
AU781438B2 (en) 2005-05-26
HK1043318A1 (en) 2002-09-13
MXPA01013406A (en) 2003-09-04
TWI283240B (en) 2007-07-01
NO324892B1 (en) 2007-12-27
CA2369308A1 (en) 2001-01-04
NO20016319D0 (en) 2001-12-21
JP2003503350A (en) 2003-01-28
IL146288A0 (en) 2002-07-25
WO2001000206A1 (en) 2001-01-04
NO20016319L (en) 2002-02-28
AU5903100A (en) 2001-01-31
CN1391473A (en) 2003-01-15
BR0012068A (en) 2002-05-14
EP1189612A1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
AR035011A1 (en) VLA-4 INHIBITING COMPOUNDS
AR035548A1 (en) ORGANIC COMPOUNDS
PE20020544A1 (en) INDOLYLMALEIMIDE DERIVATIVES
NO306399B1 (en) Condensed pyrrole carboxyanilides
CY1105899T1 (en) PYRIDINOYLOPIPIDINES AS 5-HT1F AGENTS
CO5180626A1 (en) PURINE DERIVATIVES PROTEIN QUINASA SYK INHIBITORS
YU47122B (en) 5-DEOKSI-5-FLUOROCITIDINSKI DERIVATI
NO974586D0 (en) New Substituted Biphenyl or Phenylpyridine Compounds, Methods for their Preparation and Pharmaceutical Compositions Containing Them
ES2191484T3 (en) HETEROCICLICAL COMPOUNDS AS INHIBITORS OF ROTAMASA ENZYMES.
ES2092651T3 (en) DIAZOTATED HETERO-CYCLE DERIVATIVES N-SUBSTITUTED BY A BIPHENYLMETHYLL GROUP, ITS PREPARATION, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NO832923L (en) PROCEDURE FOR PREPARING PHARMASOYYTIC ACTIVE 4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES
DK190188A (en) AROMATIC DERIVATIVES AND PROCEDURES FOR PREPARING THEM AND THEIR USE AS ANTIMICROBIAL AGENTS
DE69319925D1 (en) INDOL PIPERAZINE DERIVATIVES AS SELECTIVE LIGANDS OF THE 5HT1D AND 5HT1B RECEPTORS CAN BE USED AS MEDICINAL PRODUCTS
ES2161828T3 (en) PIPERIDINE DERIVATIVES AND ANTIPLAQUETARY AGENTS CONTAINING THEM.
DE69321609D1 (en) PIPERAZINE DERIVATIVES
ES2185316T3 (en) BUTIROLACTONAS ALFA, SUBSTITUTED BETA-CONDENSED.
FI941958A0 (en) 2-Heterocyclylethylamine derivatives and their use as medicaments
CY1110038T1 (en) 4- (diarylmethyl) -1- piperazinyl derivatives
ES471609A1 (en) A PROCEDURE FOR THE PREPARATION OF OXADIAZOLE DERIVATIVES
CO5180536A1 (en) CATEPSIN PROTEASE INHIBITORS
DK0532602T3 (en) Benzothiazole derivatives, their preparation and medicinal products containing them
NO985239L (en) Novel Metalloproteinase Inhibitors, Methods of Preparation and Pharmaceutical Compositions Containing Them
FI913656A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV ALKYL-6-PYRIDAZINDERIVAT.
DK0419360T3 (en) Phenothiazine derivatives, their preparation and pharmaceutical compositions containing them
ES2118833T3 (en) N- (MERCAPTOACIL) AMINO ACIDS, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USE, AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
FB Suspension of granting procedure